A study investigating the efficacy of anti-CD20 antibody therapy to target CD20+ T-cell lymphoma showed a close relationship between killing efficiency and the surface level of CD20 (11); a challenge also acknowledged in the treatment of CD20+ B-cell lymphomas (27). Here, MS4A1 is linked to T-cell non-Hodgkin lymphoma.